Categories
SMS Pharmaceuticals Limited — Updates, 23-05-2026: Press Release
23-05-2026 · 05:46 pm
SMS Pharma FY26 PAT surged 48% to ₹102 Cr, revenue grew 13% to ₹887 Cr. EBITDA margin expanded to 19% driven by backward integration and product mix. ₹280 Cr Capex is on track. Board announced a ₹0.40 final dividend. FY27 outlook: >15% revenue growth, 20% EBITDA margin.
No comments yet. Be the first to comment!